Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Chemoradiotherapy in Cervical Cancer
NCT00957411Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Mar 2009
- Primary completion
- Nov 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KL-140 in Cervical Cancer (CC) (2 arms), sponsored by Institut Curie. Primary endpoint: Recurrence-free survival at 2 years. Started Mar 2009; status: completed.
02
Drugs
KL-140
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00957411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00957411.